DHR Health Institute for Research and Development Acquires Mobile Research Unit to Treat COVID-19 Patients

Mobile unit to help identify and evaluate potential treatments for non-hospitalized adults with COVID-19

Translate to Spanish or other 102 languages!

Delievery of the Mobile Research Unit

Mega Doctor News

- Advertisement -

Edinburg, Texas – DHR Health Institute for Research and Development announces the arrival of the National Institutes of Health (NIH) Sponsored Mobile Research Unit.  DHR Health Institute for Research and Development is one of nine to be granted a unit by the NIH, allowing the institute to continue their mission to treat COVID-19 patients in the Rio Grande Valley. 

“We are extremely excited to partner with NIH in this initiative and to be only 1 of 9 sites in the US that has been granted by NIH with such capacity-building initiative,” said Sohail Rao, executive vice president, DHR Health and president and CEO DHR Health Institute. “The Mobile Research Unit will be used to enroll thousands of patients and volunteers in large scale clinical trials testing a variety of investigational vaccine, monoclonal antibodies and drugs intended to protect people from COVID-19 and/or treat them for acute and chronic complications of COVID-19”

Through the acquirement of the Mobile Research Unit, DHR Health Institute for Research and Development will expand the capacity to conduct innovative clinical trials that would benefit the residents of the Rio Grande Valley and treat them for chronic complications of COVID-19.  The 38×11.5 unit, that features a nurse practitioner, research nurse coordinator, driver/coordinator, three exam rooms and a lobby, will have access to enroll thousands of patients and volunteers in large clinical trials, testing a variety of investigational vaccines, monoclonal antibodies, and drugs intended to protect people from COVID-19. 

- Advertisement -

The DHR Health Institute for Research and Development is committed to providing access to innovative and advanced clinical care for patients in the Rio Grande Valley and currently has four clinical trials that will be initiated in the mobile unit immediately while other trials are being negotiated.  Committed to enrolling individuals most impacted by COVID-19, DHR Health Institute for Research and Development will work closely with the community to make participation in the trial available to those who qualify for clinical research.  In addition to a modest stipend, transportation services are also available for patients who would like to participate.

For more information about participating in a study, please call DHR Health Institute for Research and Development at 956-362-2393 or visit DHRResearch.org

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

DHR Health Expands Ophthalmology Services with Addition of Dr. Rachel Gelman

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

STHS McAllen Welcomes Aspiring Youth for an Interactive Look Inside Healthcare

As the demand for healthcare professionals continues to grow, introducing young students to the wide range of opportunities available in the medical field is more important than ever. From nurses and physicians to emergency responders, pharmacists and other essential healthcare workers, each plays a critical role in caring for patients and keeping communities healthy.

South Texas Health System Invests $25,000 in VIDA to Expand Healthcare Career Opportunities in the RGV

To help address the ongoing need for qualified workers in the Rio Grande Valley, South Texas Health System (STHS) has renewed its support of Valley Initiative for Development and Advancement (VIDA) through a $25,000 annual grant.
- Advertisement -